CRC: Clinical Trials

5 unknown. 5 Phase 2, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	5	Unknown 5
Phase 1	1	Unknown 1

Follow CRC: new trials by email Literature Review of CRC trials Research Report on CRC

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM Candonilimab (AK104), Regorafenib - CRC	Phase 2	Unknown	Jin-hong Chen	44	2024-07-11	2024-07-30
Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC HLX07, HLX10, mFOLFOX6 - CRC	Phase 2	Unknown	Shanghai Henlius Biotech	50	2022-07-15	2022-05-03
Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) HL-085, Vemurafenib - CRC	Phase 2	Unknown	Shanghai Kechow Pharma, Inc.	186	2022-02-24	2023-05-31
The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment HLX208, Cetuximab Injection [Erbitux] - CRC	Phase 2	Unknown	Shanghai Henlius Biotech	50	2021-08-11	2023-08-21
A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC SHR-1210, SHR6390 - CRC, HCC	Phase 1 / Phase 2	Unknown	Harbin Medical University	41	2018-07-30	2018-07-26

Narrower conditions

Colorectal Neoplasms (1)

Broader conditions

Colonic Diseases (1)  ·  Digestive System Diseases (1)  ·  Digestive System Neoplasms (1)  ·  Gastrointestinal Diseases (1)  ·  Gastrointestinal Neoplasms (1)  ·  Intestinal Diseases (1)  ·  Intestinal Neoplasms (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Rectal Diseases (1)

Interventions

CCT239065 (1)  ·  Cetuximab (1)  ·  HLX07 (1)  ·  Vemurafenib (1)  ·  camrelizumab (1)  ·  regorafenib (1)

Sponsors

Shanghai Henlius Biotech (2)  ·  Harbin Medical University (1)  ·  Jin-hong Chen (1)  ·  Shanghai Kechow Pharma, Inc. (1)

Countries

China (3)

Top investigators

Hongqi Tian, Ph.D (1)  ·  Peng Junjie (1)  ·  Yanqiao Zhang, PhD (1)